Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Dicembre;54(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Dicembre;54(6):599-616

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 Dicembre;54(6):599-616

MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND THERAP Y DECISION MAKING IN INFLAMMATION/INFECTION 

 REVIEWS

Clinical role of anti-granulocyte MoAb versus radiolabeled white blood cells

Ruf J., Oeser C., Amthauer H.

Klinik für Radiologie und Nuklearmedizin, University Magdeburg, Otto-von-Guericke University, Magdeburg, Germany

Scintigraphy with white blood cells (WBC), labeled with 111In-oxine or 99mTc-hexamethylpropyleneamine oxime (HMPAO), and anti-granulocyte scintigraphy using 99mTc-labeled monoclonal antibodies (MoAb), or fragments thereof, are established procedures for the diagnostic workup of infectious or inflammatory disease processes. Clinically severe afflictions such as fever of unknown origin (FUO), infectious joint replacements, osteomyelitis, vascular graft infections or cardiovascular infections often present where noninvasive proof of granulocytic inflammatory activity is more useful than mere morphology-based radiological diagnostic approaches. The labeling differences between WBC and antigranulocyte antibodies produce different pharmakokinetics and patterns of tracer accumulation and distribution. Together with the physical imaging properties of the respective isotope used for imaging, the diagnostic value of a tracer depends on the clinical setting. Thus, despite the easier and safer handling of antibody-based in-vivo labeling, indications for in-vivo labeled WBC remain. As a consequence there is as yet no ideal inflammation tracer, also bearing in mind that neither WBCs nor antibody-diagnostics can reliably differentiate sterile inflammation from infection. Although positron emission tomography (PET) using e.g. FDG-PET is replacing conventional scintigraphies in some indications, both in vivo and in vitro labelled leukocytes will remain an important clinical pillar in the diagnosis of infection and inflammation.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina